Clinical Trials
29
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- Biological: GNR-127, 80 mcgBiological: GNR-127, 20 mcgBiological: GNR-127 placeboBiological: GNR-127, 40 mcg
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 150
- Registration Number
- NCT07155499
- Locations
- 🇷🇺
National Research Center - Institute of Immunology Federal Medical-Biological Agency, Moscow, Russia
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
- Conditions
- Myocardial Infarction (MI)
- Interventions
- Biological: Revelise (GENERIUM, Russia)Biological: Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 180
- Registration Number
- NCT07146360
- Locations
- 🇷🇺
Regional State Budgetary Healthcare Institution "Altai Regional Cardiological Dispensary", Barnaul, Altayskiy Kray, Russia
🇷🇺City Budgetary Healthcare Institution of Arkhangelsk Region "First City Clinical Hospital named after E.E. Volosevich", Arkhangelsk, Arkhangelskaya oblast, Russia
🇷🇺SBHI Republican Cardiology Center, Ufa, Bashkortostan Republic, Russia
An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease
- Conditions
- Still's Disease Adult Onset
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 118
- Registration Number
- NCT06497491
- Locations
- 🇷🇺
State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital", Chelyabinsk, Chelyabinsk region, Russian Federation
🇷🇺State health care institution city clinical hospital №25, Volgograd, Volgograd region, Russian Federation
🇷🇺Limited Liability Company "Medical Center "Revma-Med", Kemerovo, Russian Federation
A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers
- Conditions
- Allergic Asthma
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 180
- Registration Number
- NCT06494345
- Locations
- 🇷🇺
State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department", Moscow, Russian Federation
A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Biological: ComplarateBiological: Actemra®
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 256
- Registration Number
- NCT06488521
- Locations
- 🇷🇺
State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department", Moscow, Russian Federation
🇷🇺Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov Ministry of Health of Russia, Moscow, Russian Federation
🇷🇺LLC "X Seven Clinical Research", Saint Petersburg, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next